STEER was a retrospective, observational real-world study, evaluating the efficacy of Wegovy (semaglutide) 2.4 mg versus tirzepatide in lowering the risk of MACE in US adults with overweight or obesity and established CVD with no prior history of diabetes, with a primary outcome measure of revised 5-point MACE (heart attack, stroke, hospitalization for heart failure, coronary revascularization, and death from any cause) and revised 3-point MACE (heart attack, stroke and death from any cause)
doi: 10.1039/c7fo00809k, 76 MaherP
Only 1.6% of participants discontinued due to nausea, meaning the vast majority found it manageable over time (Wilding et al., NEJM 2021)
Whether youve been taking it for diabetes or weight management, if youve noticed some unwelcome changes to your bowel movements, know that youre not alone